Boost for biosimilar switching as Finns add their backing
This article was originally published in Scrip
Executive Summary
Finland's Fimea has become the latest national regulatory agency in the EU to issue a formal statement supporting the switching of patients from a reference biological product to a biosimilar version – and vice versa – on the grounds that there is no evidence that doing so causes any adverse effects.